Deaths by overdose are up 23% this year and there is a drug that can save many of the nearly 13,000, if it could only be available. The drug Naloxone, which we see used on television all the time, pulling overdose victims from the brink of death in seconds, is under patent by Kaleo Pharmaceuticals, a Virginia based company whose management team is listed below.
The injectable version has gone up 200% over night while the nasal spray is up 500% and both are expected to keep soaring.
Spencer is President, Chief Executive Officer and a member of our board of directors. Prior to joining kaléo, he spent 15 years with Guidant Corporation (now Boston Scientific Corporation) in a variety of sales, marketing, business development and general management positions. He began his career in the Medical Devices and Diagnostics (MDD) Division of Eli Lilly & Company, which was spun off from Lilly to become Guidant in 1994. Spencer serves on the board of directors of several private life science companies and is a member of the VABIO (Virginia Biotechnology Association) board of directors.
Spencer holds a BS in Civil Engineering from the Virginia Military Institute, and an MBA from the University of North Carolina, Chapel Hill.
Spencer is a 2013 Ernst & Young Entrepreneur Of The Year® Award Winner.
Dan is our Chief Commercial Officer. He is responsible for leading our commercial efforts and building a best-in-class team and commercial capability to help drive our growth. Dan has over 20 years of global leadership experience in a variety of general management, commercial operations, legal and functional roles. He began his career as a commercial lawyer before joining Guidant/Boston Scientific where he served on the senior leadership teams for the US sales organization, the Cardiac Rhythm Management (CRM) business unit and the Asia Pacific region. Most recently, Dan was part of the Sorin Group CRM global leadership team where he ran the US CRM business before creating a start-up initiative within Sorin to pilot and launch innovative new business models.
Dan has a B.S. In Business Administration, cum laude, from Illinois State University and a J.D., magna cum laude, from Indiana University.
As Vice President and Chief Compliance Officer, Kim is responsible for all ethics and compliance matters affecting kaléo. She has more than 20 years of legal, compliance and regulatory experience in the biopharmaceutical industry. Prior to joining kaléo, Kim spent more than 11 years at Amgen in both Law and Compliance where she served as Associate General Counsel and Executive Director of Worldwide Compliance and Business Ethics. Immediately before joining kaléo, Kim served as Vice President and Compliance Officer at Impax Laboratories, Inc.
Kim received her JD cum laude from the Pepperdine University School of Law, and her BA cum laude from Sweet Briar College.
Eric is Vice President of Product Strategy for kaléo. He is responsible for both co-founding our company and co-inventing our technology platforms.
Eric received a BS in Biology with honors from Virginia Commonwealth University (VCU), received his Ph.D in the pharmaceutical sciences from VCU’s School of Pharmacy and his MD from the VCU’s School of Medicine (formerly the Medical College of Virginia).
As Vice President of Product Development and Industrialization, Evan manages all areas of our invention and design process, including kaléo‘s intellectual property portfolio. In addition, he is a co-founder of our company and the co-inventor of our technology platforms.
Evan has been recognized among his peers for his expertise and work in human factors engineering (HFE) and is actively involved with the Human Factors & Ergonomics Society (HFES). He serves on the Medical Devices for Injection and Human Factors Committees for the Association of the Advancement of Medical Instrumentation (AAMI).
Evan is a graduate of the University of Virginia where he earned a BS in Mechanical Engineering and an MS in Systems Engineering with a concentration on HFE.
Ron is kaléo‘s Chief Operating Officer. He is responsible for directing all aspects of our drug development and regulatory affairs, including clinical development. Ron has over 25 years of pharmaceutical/biotechnology development and operations experience. Prior to joining kaléo, Ron served as Executive Vice President and Chief Operating Officer for Insmed Incorporated where his responsibilities included R&D, Regulatory Affairs, Finance, Manufacturing and Quality Assurance. Ron has directed the strategic development, compilation, submission and management of several INDs and NDAs. Prior to joining Insmed, he held several clinical, business development and operational positions with domestic and foreign companies within the pharmaceutical industry.
Ron received a BS from Radford University and received his MS in Statistics and MBA from Virginia Commonwealth University.
Mark is kaléo’s Vice President of Corporate Affairs. He is responsible for corporate communications, public relations, governmental affairs, alliance development and community relations. Mark has more than 15 years of experience in the biopharmaceutical and clinical laboratory industries. Prior to joining kaléo, Mark held the position of senior vice president for corporate and governmental affairs with a leading advanced diagnostic clinical laboratory, where he headed the team responsible for government affairs, alliance development and corporate relations. Mark also served for nearly twelve years as the leader of the Virginia Biotechnology Association, advocating for the advancement of the $13 billion biotechnology and medical device industry in the Commonwealth.
Mark is a graduate of the College of William and Mary and received his MBA from Virginia Commonwealth University.
Chuck is kaléo‘s Vice President of Global Supply Chain and Manufacturing. He is responsible for managing all aspects of commercial production including planning, procurement, logistics and contract manufacturing. Chuck has over 25 years of clinical and commercial operations experience in the biotech, pharmaceutical, electronics, and aerospace industries. Prior to joining kaléo, Chuck led Global Supply Chain Operations for MedImmune, LLC. Besides managing corporate and site supply chain functions at all domestic and international locations, he was responsible for the implementation and oversight of the MedImmune Enterprise Resource Planning system. Prior to joining MedImmune, he held several leadership positions at domestic companies in operations management and manufacturing engineering.
Chuck received his MBA from the University of North Carolina at Wilmington and a BS in Industrial Engineering from Texas A&M University.
Ann is kaléo’s Vice President of Quality Assurance and is responsible for establishing and maintaining the quality systems for the development and production of pharmaceutical, device and combination products. Ann has over 30 years of quality, regulatory and compliance experience in the pharmaceutical, biologics, medical device and consumer products industries from late stage development and through commercialization.
Prior to joining kaléo, Ann held a number of quality and compliance related positions at Hoechst-Roussel Pharmaceuticals (now Sanofi) and multiple Johnson & Johnson companies. Immediately prior to joining kaléo, she acted as the Head of Quality, US Supply Chain for Valeant Pharmaceuticals and had responsibilities for managing all quality aspects for contract manufacturing and supplier quality programs.
Ann received her BA degree with honors in Chemistry and Biology from Mount Saint Mary College, and an MS in Chemistry from Fairleigh Dickinson University.
Ned is kaléo‘s Vice President and General Counsel. He is responsible for all legal matters affecting kaléo. Ned has over 20 years experience representing emerging growth companies in the life sciences and technology sectors spending the majority of his career working in Silicon Valley. He has helped build numerous companies from formation to successful public offering and acquisition, including PayPal (acquired by eBay), Infinera (INFN) and Eos Biotechnology (acquired by Protein Design Labs). Prior to joining kaléo, Ned was a partner in the Emerging Companies Group at Orrick, Herrington & Sutcliffe LLP.
Ned received his JD and MBA from the College of William & Mary and received his BA from the University of Texas.
Chris, our Chief Financial Officer, has over 20 years of experience in a broad range of management, treasury, financial and accounting roles. Prior to joining kaléo, Chris served as Vice President of Planning & Analysis for LandAmerica Financial Group, Inc. He also spent 11 years with Cadmus Communications Corporation, including 5 years as Vice President and Treasurer. Chris began his career in public accounting at Coopers & Lybrand, LLP.
Chris holds a BS in Commerce, with a concentration in Accounting, from the University of Virginia. He is a CPA licensed in the Commonwealth of Virginia.
Mark served as kaléo‘s Vice President of Industrialization and Quality. He was responsible for the engineering, late phase development and quality assurance activities for our company. Mark had been in the medical device industry for more than 25 years working at Bayer USA and Medtronic, as well as a number of start-up companies. He had been granted 25 patents in the medical device field and was a member of both the Society for Biomaterials and the American Association of Pharmaceutical Sciences.
Mark earned a Masters degree in Colloids, Polymers, Surfaces, and Biomedical Engineering from Carnegie-Mellon University.
Gordon Duff is a Marine combat veteran of the Vietnam War. He is a disabled veteran and has worked on veterans and POW issues for decades. Gordon is an accredited diplomat and is generally accepted as one of the top global intelligence specialists. He manages the world’s largest private intelligence organization and regularly consults with governments challenged by security issues.
Duff has traveled extensively, is published around the world and is a regular guest on TV and radio in more than “several” countries. He is also a trained chef, wine enthusiast, avid motorcyclist and gunsmith specializing in historical weapons and restoration. Business experience and interests are in energy and defense technology.
ATTENTION READERS Due to the nature of independent content, VT cannot guarantee content validity. We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.
All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.